These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16384814)

  • 1. Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.
    Kouimtsidis C; Schifano F; Sharp T; Ford L; Robinson J; Magee C
    Psychosomatics; 2006; 47(1):86-7. PubMed ID: 16384814
    [No Abstract]   [Full Text] [Related]  

  • 2. Ecstasy (MDMA) and memory function: a meta-analytic update.
    Laws KR; Kokkalis J
    Hum Psychopharmacol; 2007 Aug; 22(6):381-8. PubMed ID: 17621368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is a dose of ecstasy?
    Cole JC; Sumnall HR; Wagstaff GF
    J Psychopharmacol; 2002 Jun; 16(2):189-90. PubMed ID: 12095080
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
    Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective neurocognitive deficits associated with multiple doses of ecstasy/MDMA: a reply to Cole.
    Fox HC; Parrott AC
    J Psychopharmacol; 2003 Jun; 17(2):242-4. PubMed ID: 12870575
    [No Abstract]   [Full Text] [Related]  

  • 6. Methodological problems with ecstasy and the SCL-90.
    Cole JC; Sumnall HR; Wagstaff GF
    Psychopharmacology (Berl); 2002 Jul; 162(2):215-7; discussion 218-22. PubMed ID: 12110999
    [No Abstract]   [Full Text] [Related]  

  • 7. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug.
    Fox HC; Parrott AC; Turner JJ
    J Psychopharmacol; 2001 Dec; 15(4):273-81. PubMed ID: 11769821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy").
    Cohen RS
    Biol Psychiatry; 1996 May; 39(9):819-20. PubMed ID: 8731525
    [No Abstract]   [Full Text] [Related]  

  • 10. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?
    Morgan MJ; McFie L; Fleetwood H; Robinson JA
    Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients.
    Schifano F; Di Furia L; Forza G; Minicuci N; Bricolo R
    Drug Alcohol Depend; 1998 Sep; 52(1):85-90. PubMed ID: 9788011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users.
    Gouzoulis-Mayfrank E; Thimm B; Rezk M; Hensen G; Daumann J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):819-27. PubMed ID: 12921915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports].
    Bango J; Fadón P; Mata F; Rubio G; Santo-Domingo J
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(4):260-3. PubMed ID: 9807860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review.
    Montoya AG; Sorrentino R; Lukas SE; Price BH
    Harv Rev Psychiatry; 2002; 10(4):212-20. PubMed ID: 12119307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everyday memory deficits in ecstasy-polydrug users.
    Montgomery C; Fisk JE
    J Psychopharmacol; 2007 Sep; 21(7):709-17. PubMed ID: 17606476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of ecstasy on the body].
    Saarijärvi S; Lopperi M
    Duodecim; 2003; 119(13):1211-5. PubMed ID: 12908183
    [No Abstract]   [Full Text] [Related]  

  • 18. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users.
    Schilt T; de Win MM; Jager G; Koeter MW; Ramsey NF; Schmand B; van den Brink W
    Psychol Med; 2008 Sep; 38(9):1309-17. PubMed ID: 17988417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study.
    Schilt T; de Win MM; Koeter M; Jager G; Korf DJ; van den Brink W; Schmand B
    Arch Gen Psychiatry; 2007 Jun; 64(6):728-36. PubMed ID: 17548754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.